Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Heath Lukatch - aVenture Research

Heath Lukatch

AddedMar 31, 2024

UpdatedOct 18, 2026

Heath Lukatch

Heath Lukatch

Founder, Red Tree Venture Capital.

Heath Lukatch's Career

Red Tree Venture Capital.

Investment Firm

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Portola, CA, US

Founder

SightLine Partners

Investment FirmBloomington, MN, US

Co-Founder

AnaptysBio

Public$85.9MSan Diego, CA, US

Board Member· Board

Inogen

Public$73.3MGoleta, CA, US

Board Member· Board

Acrigen Biosciences

Seed$1.2MAlameda, CA, US

Board Member· Board

Adynxx

$23.5MSan Francisco, CA, US

Board Member· Board

ViewPoint Therapeutics

$39MSan Francisco, CA, US

Board Member· Board

People Similar to Heath Lukatch

Santhosh PalaniBoard Member · Caribou Biosciences

Jennifer DoudnaBoard Member · Johnson & Johnson

John SantiniBoard Member · On Demand Therapeutics

Shalini SharpBoard Member · Neurocrine Biosciences

Feng ZhangCo-Founder · Beam Therapeutics

Jim MullenBoard Member · Thermo Fisher Scientific

Similar to Red Tree Venture Capital.

Reddy Capital PartnersLos Angeles, CA, USest. 2007Reddy Capital PartnersLos Angeles, CA, US · est. 2007

Reddy Capital Partners LLC: A US-based venture capital firm specializing in early-stage financing.

Investment Firm5

Redhill CapitalGuangzhou, Guangdong, CNest. 2018Redhill CapitalGuangzhou, Guangdong, CN · est. 2018

Redhill Capital: Early-stage venture capital firm primarily investing in the medical industry.

Investment Firm30

Redwood Venture PartnersLos Altos, CA, USest. 1997Redwood Venture PartnersLos Altos, CA, US · est. 1997

Redwood Venture Partners, LLC: A US-based venture capital firm investing in communication, mobility, and IT industries.

Investment Firm30

Red Abbey Venture PartnersBaltimore, MD, USest. 2004Red Abbey Venture PartnersBaltimore, MD, US · est. 2004

Red Abbey Venture Partners, LP: A US-based venture capital firm investing in life sciences companies.

Investment Firm7

Leadership at Adynxx

Dennis PodlesakBoard Member

Stan AbelBoard Member

Eckard WeberBoard Member

Julien MametBoard Member

Pierre LegaultBoard Member

Rick OrrBoard Member

Similar to Adynxx

XdyniaCharlottesville, VA, USPharmaceuticalsest. 2012XdyniaCharlottesville, VA, US · est. 2012

Xdynia LLC, a pharmaceutical startup, develops drugs to prevent and treat neuropathic pain.

Series A · $262.5k5

Leadership at SightLine Partners

Rob ShurtleffCo-Founder

Charles J. 'Chuck' LicariBoard Member

Similar to SightLine Partners

ExSight VenturesNew York City, NY, USest. 2014ExSight VenturesNew York City, NY, US · est. 2014

ExSight Ventures: A venture capital firm funding early-stage ophthalmic solutions in biotech, medical devices, and software.

Investment Firm8

Endeavour VisionGeneva, Canton of Geneva, CHest. 2000Endeavour VisionGeneva, Canton of Geneva, CH · est. 2000

Endeavour Vision SA: A leading private equity firm investing in growth-stage medtech innovations.

Investment Firm38

Kline Hill PartnersGreenwich, CT, USest. 2015Kline Hill PartnersGreenwich, CT, US · est. 2015

Kline Hill Partners LLC: A US-based private equity firm investing in venture capital, buyout funds, energy, and real estate.

Investment Firm48

Waterline VenturesCambridge, MA, USest. 2014Waterline VenturesCambridge, MA, US · est. 2014

Waterline Ventures, LLC: A US-based venture capital firm investing in technology sectors.

Investment Firm7

Leadership at AnaptysBio

John OrwinBoard Member

Jamie TopperBoard Member

J. Anthony WareBoard Member

Andrea CubittCo-Founder

Hollings RentonBoard Member

Magda MarquetBoard Member

Similar to AnaptysBio

ImmunityBioCulver City, CA, USCancer Treatment, Immunotherapyest. 2014ImmunityBioCulver City, CA, US · est. 2014

ImmunityBio, Inc.: A US-based biotech firm specializing in immunotherapy for cancer and infectious diseases.

Public · $103.5M51

Leadership at Inogen

Raymond HuggenbergerBoard Member

Ali BauerleinCo-Founder

Christine M KingBoard Member

Steve CooperBoard Member

Scott A BeardsleyBoard Member

Byron MyersBoard Member

Similar to Inogen

PulmonxRedwood City, CA, USMedical Devicesest. 1998PulmonxRedwood City, CA, US · est. 1998

Pulmonx Corp., based in Redwood City, US, globally develops and markets medical devices for pulmonary disorders.

Public · $276.9M269

Leadership at Acrigen Biosciences

David RabukaCo-Founder

Joe Bondy-DenomyCo-Founder

Similar to Acrigen Biosciences

Editas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226

MetagenomiEmeryville, CA, USGene Editingest. 2016MetagenomiEmeryville, CA, US · est. 2016

Metagenomi: Pioneering next-gen gene-editing systems to treat genetic diseases.

Public · $457M191

Emendo BiotherapeuticsNew York City, NY, USGene Editingest. 2015Emendo BiotherapeuticsNew York City, NY, US · est. 2015

Emendo Biotherapeutics: Advancing gene therapy with next-gen gene-editing tools for genetic disorders.

Tome BiosciencesWatertown, MA, USGene Editingest. 2021Tome BiosciencesWatertown, MA, US · est. 2021

Tome Biosciences: Pioneering programmable gene insertion via CRISPR for precise genome editing.

Series A · $213M88

Leadership at ViewPoint Therapeutics

Jason GestwickiCo-Founder

Leah MakleyCo-Founder

Ed HurwitzBoard Member

Similar to ViewPoint Therapeutics

Visus TherapeuticsSeattle, WA, USEye Dropsest. 2019Visus TherapeuticsSeattle, WA, US · est. 2019

Visus Therapeutics: Pioneering presbyopia-correcting eye drops with 8-hour potential.

Series B · $56M45

VisioxTarrytown, NY, USTherapeuticsest. 2022VisioxTarrytown, NY, US · est. 2022

Visiox: A privately-funded biopharmaceutical firm innovating new treatments for prevalent ophthalmic diseases.

Lenz TherapeuticsDel Mar, CA, USPharmaceuticalsest. 2013Lenz TherapeuticsDel Mar, CA, US · est. 2013

LENZ Therapeutics: Innovating vision-enhancing ophthalmic pharmaceuticals.

Series B · $133.9M14

Vian TherapeuticsSan Francisco, CA, USPharmaceuticals, Therapeuticsest. 2023Vian TherapeuticsSan Francisco, CA, US · est. 2023

VIAN Therapeutics: A virtual pharma startup pioneering non-invasive solutions for retinal diseases.

SnowdonJersey City, NJ, USDrugs, Pharmaceuticalsest. 2005

SnowdonJersey City, NJ, US · est. 2005

Snowdon Inc., a US-based pharmaceutical company, focuses on developing safe, effective drugs for pain, neurological disorders, and infectious diseases.

Public · $500k4

AcelRx PharmaceuticalsRedwood City, CA, USPharmaceuticalsest. 2005AcelRx PharmaceuticalsRedwood City, CA, US · est. 2005

AcelRx Pharmaceuticals (rebranded as Talphera, Nasdaq: TLPH) develops innovative specialty therapies for medically supervised healthcare settings.

AptinyxEvanston, IL, USPharmaceuticalsest. 2015AptinyxEvanston, IL, US · est. 2015

Aptinyx Inc., a US-based bio-pharmaceutical company, specializes in developing novel treatments for brain and nervous system disorders.

Public · $273.9M12

Anthera PharmaceuticalsHayward, CA, USPharmaceuticalsest. 2004

Anthera PharmaceuticalsHayward, CA, US · est. 2004

Anthera Pharmaceuticals: A US biopharma firm specializing in inflammation and autoimmune disease treatments.

Public · $101.5M21

Santa Ana BioAlameda, CA, USBiologics, Therapiesest. 2021Santa Ana BioAlameda, CA, US · est. 2021

Santa Ana Bio designs precision biologics using deep cell profiling tech, specializing in autoimmune diseases.

Series A · $35.3M18

Rapt TherapeuticsSouth San Francisco, CA, USPharmaceuticalsest. 2015Rapt TherapeuticsSouth San Francisco, CA, US · est. 2015

RAPT Therapeutics, a global pharmaceutical company, specializes in immunology and small molecule drug discovery to combat cancer and allergies.

Public · $440.2M195

Invent MedicalCarlsbad, CA, USMedical Devicesest. 2014

Invent MedicalCarlsbad, CA, US · est. 2014

Invent Respiratory: Developing advanced respiratory care devices for patient recovery and rehabilitation.

Seed · $258.1k6

Rapid OxygenStamford, CT, USMedical Devicesest. 2016Rapid OxygenStamford, CT, US · est. 2016

Rapid Oxygen: Medtech firm offering FDA-cleared, portable, non-explosive oxygen devices for emergencies.

Series A · $5.5M75

GO² DevicesHouston, TX, USMedical Devices, Oxygen Therapyest. 2016GO² DevicesHouston, TX, US · est. 2016

GO2: Enhancing oxygen for athletes, climbers, and medical recovery. Innovating for telemedicine and real-time analysis.

Pre-Seed · $200k6